Oppenheimer & Co’s Axsome Therapeutics AXSM Stock Holding History

Oppenheimer & Co’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,076	Closed	-$1.29M	–	1692
2025 Q4	$1.29M	Buy	+7,076	New	+$988K	0.02%	693

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's AXSM Position: Q1 2026 in Review

Oppenheimer & Co sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 7,076 shares — an estimated $1.29M sold.

Oppenheimer & Co first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $1.29M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Oppenheimer & Co reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Oppenheimer & Co sold 7,076 Axsome Therapeutics shares in Q1 2026, an estimated $1.29M.
Oppenheimer & Co first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
Oppenheimer & Co's Axsome Therapeutics position peaked at $1.29M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.